Several small molecule inhibitors targeting DNA methyltransferases (DNMTs), histone deacetylases (HDACs) and janus kinase 2 (JAK2) have already been granted approval by the US Food and Drug Administration (FDA) for the treatment of certain cancers [4–6]. The gene discussed is JAK2; the disease is cancer.